HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients
Amplification and/or overexpression of HER-2/neu has been reported to be associated with poor prognosis in breast cancer. One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported t...
Gespeichert in:
| Veröffentlicht in: | Genetic testing and molecular biomarkers 2011-03, Vol.15 (3), p.143-146 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 3 |
| container_start_page | 143 |
| container_title | Genetic testing and molecular biomarkers |
| container_volume | 15 |
| creator | Sezgin, Ezgi Sahin, Feride Iffet Yagmurdur, Mahmut Can Demirhan, Beyhan |
| description | Amplification and/or overexpression of HER-2/neu has been reported to be associated with poor prognosis in breast cancer. One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported to be associated with increased risk of breast cancer. However, several studies have shown that this association is controversial. In this study, we aimed to evaluate the association between HER-2 codon 655 polymorphisms and breast cancer risk in breast cancer patients. We analyzed the HER-2 codon 655 polymorphisms in paraffin block sections from 58 breast cancer patients and 55 control subjects and evaluated the association of the polymorphic alleles with breast cancer. Following DNA isolation, polymerase chain reaction-restriction fragment length polymorphism analysis was carried out. The polymorphic Val allele was detected in 12.1% of the patients and in 17.3% of the control subjects. When the results of the study were evaluated, no statistically significant correlation was found between HER-2/neu codon 655 polymorphism and breast cancer. |
| doi_str_mv | 10.1089/gtmb.2010.0126 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_954645036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A252291313</galeid><sourcerecordid>A252291313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-c7a0f42b4118b43666488a0d189e149fb9e1af543469cf077acf83e7669ab7bb3</originalsourceid><addsrcrecordid>eNqFkc9rFDEUx4NYbK29epSAB_Uwu_k9k2Mp1RYWCqK9hiT7skZmkjGZPfS_N0NrTwXJ4Zs8Pu_lwQeh95RsKBn09rBMbsNIexLK1Ct0RrWQHWGyf_18V_IUva31NyFK8EG9QaeMMiJ6os7Q7ub6e8e2CY74AAmwz_ucsJISf74dYXtvxy94zuPDlMv8K9YJx4RdAVsX7G3xMeXJ4tkuEdJS36GTYMcKF095jn5-vf5xddPt7r7dXl3uOs81XzrfWxIEc4LSwQmulBLDYMmeDhqo0MG1sEEKLpT2gfS99WHg0Culreud4-fo0-PcueQ_R6iLmWL1MI42QT5Wo6VQQhKu_ksO7ZdeE00b-fGRPNgRTEwhL8X6lTaXTDLWEMobtXmBamcPU_Q5QYit_lKDL7nWAsHMJU62PBhKzGrQrAbNatCsBlvDh6eNj26C_TP-Txn_C5LZkuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>854379091</pqid></control><display><type>article</type><title>HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Sezgin, Ezgi ; Sahin, Feride Iffet ; Yagmurdur, Mahmut Can ; Demirhan, Beyhan</creator><creatorcontrib>Sezgin, Ezgi ; Sahin, Feride Iffet ; Yagmurdur, Mahmut Can ; Demirhan, Beyhan</creatorcontrib><description>Amplification and/or overexpression of HER-2/neu has been reported to be associated with poor prognosis in breast cancer. One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported to be associated with increased risk of breast cancer. However, several studies have shown that this association is controversial. In this study, we aimed to evaluate the association between HER-2 codon 655 polymorphisms and breast cancer risk in breast cancer patients. We analyzed the HER-2 codon 655 polymorphisms in paraffin block sections from 58 breast cancer patients and 55 control subjects and evaluated the association of the polymorphic alleles with breast cancer. Following DNA isolation, polymerase chain reaction-restriction fragment length polymorphism analysis was carried out. The polymorphic Val allele was detected in 12.1% of the patients and in 17.3% of the control subjects. When the results of the study were evaluated, no statistically significant correlation was found between HER-2/neu codon 655 polymorphism and breast cancer.</description><identifier>ISSN: 1945-0265</identifier><identifier>EISSN: 1945-0257</identifier><identifier>DOI: 10.1089/gtmb.2010.0126</identifier><identifier>PMID: 21204706</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adult ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Case-Control Studies ; Codon ; Codon - genetics ; Development and progression ; Female ; Genes, erbB-2 - genetics ; Genetic aspects ; Genotype ; Humans ; Middle Aged ; Physiological aspects ; Polymerase Chain Reaction ; Polymorphism, Genetic ; Polymorphism, Restriction Fragment Length ; Receptor, ErbB-2 - genetics ; Risk Factors ; Single nucleotide polymorphisms</subject><ispartof>Genetic testing and molecular biomarkers, 2011-03, Vol.15 (3), p.143-146</ispartof><rights>COPYRIGHT 2011 Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-c7a0f42b4118b43666488a0d189e149fb9e1af543469cf077acf83e7669ab7bb3</citedby><cites>FETCH-LOGICAL-c393t-c7a0f42b4118b43666488a0d189e149fb9e1af543469cf077acf83e7669ab7bb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21204706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sezgin, Ezgi</creatorcontrib><creatorcontrib>Sahin, Feride Iffet</creatorcontrib><creatorcontrib>Yagmurdur, Mahmut Can</creatorcontrib><creatorcontrib>Demirhan, Beyhan</creatorcontrib><title>HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients</title><title>Genetic testing and molecular biomarkers</title><addtitle>Genet Test Mol Biomarkers</addtitle><description>Amplification and/or overexpression of HER-2/neu has been reported to be associated with poor prognosis in breast cancer. One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported to be associated with increased risk of breast cancer. However, several studies have shown that this association is controversial. In this study, we aimed to evaluate the association between HER-2 codon 655 polymorphisms and breast cancer risk in breast cancer patients. We analyzed the HER-2 codon 655 polymorphisms in paraffin block sections from 58 breast cancer patients and 55 control subjects and evaluated the association of the polymorphic alleles with breast cancer. Following DNA isolation, polymerase chain reaction-restriction fragment length polymorphism analysis was carried out. The polymorphic Val allele was detected in 12.1% of the patients and in 17.3% of the control subjects. When the results of the study were evaluated, no statistically significant correlation was found between HER-2/neu codon 655 polymorphism and breast cancer.</description><subject>Adult</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Case-Control Studies</subject><subject>Codon</subject><subject>Codon - genetics</subject><subject>Development and progression</subject><subject>Female</subject><subject>Genes, erbB-2 - genetics</subject><subject>Genetic aspects</subject><subject>Genotype</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Physiological aspects</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Genetic</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Risk Factors</subject><subject>Single nucleotide polymorphisms</subject><issn>1945-0265</issn><issn>1945-0257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9rFDEUx4NYbK29epSAB_Uwu_k9k2Mp1RYWCqK9hiT7skZmkjGZPfS_N0NrTwXJ4Zs8Pu_lwQeh95RsKBn09rBMbsNIexLK1Ct0RrWQHWGyf_18V_IUva31NyFK8EG9QaeMMiJ6os7Q7ub6e8e2CY74AAmwz_ucsJISf74dYXtvxy94zuPDlMv8K9YJx4RdAVsX7G3xMeXJ4tkuEdJS36GTYMcKF095jn5-vf5xddPt7r7dXl3uOs81XzrfWxIEc4LSwQmulBLDYMmeDhqo0MG1sEEKLpT2gfS99WHg0Culreud4-fo0-PcueQ_R6iLmWL1MI42QT5Wo6VQQhKu_ksO7ZdeE00b-fGRPNgRTEwhL8X6lTaXTDLWEMobtXmBamcPU_Q5QYit_lKDL7nWAsHMJU62PBhKzGrQrAbNatCsBlvDh6eNj26C_TP-Txn_C5LZkuQ</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>Sezgin, Ezgi</creator><creator>Sahin, Feride Iffet</creator><creator>Yagmurdur, Mahmut Can</creator><creator>Demirhan, Beyhan</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201103</creationdate><title>HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients</title><author>Sezgin, Ezgi ; Sahin, Feride Iffet ; Yagmurdur, Mahmut Can ; Demirhan, Beyhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-c7a0f42b4118b43666488a0d189e149fb9e1af543469cf077acf83e7669ab7bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Case-Control Studies</topic><topic>Codon</topic><topic>Codon - genetics</topic><topic>Development and progression</topic><topic>Female</topic><topic>Genes, erbB-2 - genetics</topic><topic>Genetic aspects</topic><topic>Genotype</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Physiological aspects</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Genetic</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Risk Factors</topic><topic>Single nucleotide polymorphisms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sezgin, Ezgi</creatorcontrib><creatorcontrib>Sahin, Feride Iffet</creatorcontrib><creatorcontrib>Yagmurdur, Mahmut Can</creatorcontrib><creatorcontrib>Demirhan, Beyhan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Genetic testing and molecular biomarkers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sezgin, Ezgi</au><au>Sahin, Feride Iffet</au><au>Yagmurdur, Mahmut Can</au><au>Demirhan, Beyhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients</atitle><jtitle>Genetic testing and molecular biomarkers</jtitle><addtitle>Genet Test Mol Biomarkers</addtitle><date>2011-03</date><risdate>2011</risdate><volume>15</volume><issue>3</issue><spage>143</spage><epage>146</epage><pages>143-146</pages><issn>1945-0265</issn><eissn>1945-0257</eissn><abstract>Amplification and/or overexpression of HER-2/neu has been reported to be associated with poor prognosis in breast cancer. One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported to be associated with increased risk of breast cancer. However, several studies have shown that this association is controversial. In this study, we aimed to evaluate the association between HER-2 codon 655 polymorphisms and breast cancer risk in breast cancer patients. We analyzed the HER-2 codon 655 polymorphisms in paraffin block sections from 58 breast cancer patients and 55 control subjects and evaluated the association of the polymorphic alleles with breast cancer. Following DNA isolation, polymerase chain reaction-restriction fragment length polymorphism analysis was carried out. The polymorphic Val allele was detected in 12.1% of the patients and in 17.3% of the control subjects. When the results of the study were evaluated, no statistically significant correlation was found between HER-2/neu codon 655 polymorphism and breast cancer.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>21204706</pmid><doi>10.1089/gtmb.2010.0126</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1945-0265 |
| ispartof | Genetic testing and molecular biomarkers, 2011-03, Vol.15 (3), p.143-146 |
| issn | 1945-0265 1945-0257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954645036 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Breast cancer Breast Neoplasms - genetics Breast Neoplasms - pathology Case-Control Studies Codon Codon - genetics Development and progression Female Genes, erbB-2 - genetics Genetic aspects Genotype Humans Middle Aged Physiological aspects Polymerase Chain Reaction Polymorphism, Genetic Polymorphism, Restriction Fragment Length Receptor, ErbB-2 - genetics Risk Factors Single nucleotide polymorphisms |
| title | HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T04%3A19%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER-2/neu%20gene%20codon%20655%20(Ile/Val)%20polymorphism%20in%20breast%20carcinoma%20patients&rft.jtitle=Genetic%20testing%20and%20molecular%20biomarkers&rft.au=Sezgin,%20Ezgi&rft.date=2011-03&rft.volume=15&rft.issue=3&rft.spage=143&rft.epage=146&rft.pages=143-146&rft.issn=1945-0265&rft.eissn=1945-0257&rft_id=info:doi/10.1089/gtmb.2010.0126&rft_dat=%3Cgale_proqu%3EA252291313%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=854379091&rft_id=info:pmid/21204706&rft_galeid=A252291313&rfr_iscdi=true |